ClinicalTrials.gg
RecruitingNCT07215663Updated Sep 2, 2026

Clinical Study of Cizutamig in Systemic Lupus Erythematosus

A Phase 1 interventional study of Cizutamig in Systemic Lupus Erythematosus (SLE), sponsored by Candid Therapeutics. Recruiting at 17 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Candid Therapeutics (part of UCB S.A.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Lupus Erythematosus, Systemic by UCB S.A. — 4 open to participants now, 4 under way, 2 of them phase 3. Lupus Erythematosus, Systemic · UCB S.A..

Planned enrollment
12th of 21
47 · median 54
Started
2025
the only one that year
Phase 1
5 of 21
2 open now
Registered
20th of 21
by date

Among the 21 studies in Lupus Erythematosus, Systemic by UCB S.A., this one is the 12th largest by planned enrollment, is the only one that started in 2025, is one of 5 in phase 1, and was the 20th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 21 studies in Lupus Erythematosus, Systemic by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Lupus Erythematosus, Systemic by UCB S.A., or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Systemic Lupus Erythematosus

Read the detailed description

This is a Phase 1b, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of cizutamig in patients with Systemic Lupus Erythematosus

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 75 years old at the time of signing the form
  2. Diagnosis of SLE according to the ACR/EULAR classification criteria
  3. Positive anti-dsDNA or positive anti-Smith antibodies AND positive for at least one other of anti-dsDNA, anti-Smith antibodies, or ANA ≥1:80 at screening
  4. SLEDAI-2K total score ≥6 and SLEDAI-2K clinical score≥4 at Screening
  5. The investigator judged that the patient had an inadequate response to prior treatment for at least 3 months before screening
  6. Stable use of concomitant therapies
  7. For patients with active LN only: LN Class III or IV

Exclusion criteria

Exclusion Criteria:

  1. Inadequate clinical laboratory parameters at Screening
  2. Active infection
  3. Receipt of or inability to discontinue any excluded therapies
  4. Receipt of within 4 weeks prior to Screening
  5. Presence of any concomitant disease
  6. Active or known history of catastrophic anti-phospholipid syndrome (APS)
  7. APS or thrombotic event not adequately controlled by anticoagulation therapy
  8. History of progressive multifocal leukoencephalopathy
  9. History of primary immunodeficiency or a hereditary deficiency of the complement system
  10. Central nervous system disease
  11. Presence of 1 or more significant concurrent medical conditions
  12. Have a diagnosis or history of malignant disease within 5 years
  13. Serious mental illness, alcohol or drug abuse, dementia, or any other condition that would impair the patient's ability to receive the planned treatment or to understand at the study site as determined by local practice
  14. Inability to comply with protocol-mandated requirements
  15. History of severe allergic or anaphylactic reactions to mAb therapy (or recombinant antibody-related fusion proteins) or any constituents of cizutamig
  16. History of or planned organ transplant and/or or allogeneic hematopoietic stem cell transplantation
  17. Major surgery requiring use of general anesthesia within 12 weeks or planned or expected major surgery during the study
  18. Women who are pregnant or breastfeeding
  19. Patients who do not agree to the use of highly effective as defined by the protocol
  20. Individuals considered to be part of a vulnerable population (eg, incarceration)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (estimated)

Study arms

  • Experimental
    Cizutamig

    Drug: Cizutamig

Interventions

  • Cizutamig will be dosed according to the protocol

    Also known as: CND106

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events through end of study

    Time frame: Baseline to Month 12

  2. Changes from baseline in vital signs through end of study: body temperature

    Time frame: Baseline to Month 12

  3. Changes from baseline in vital signs through end of study: heart rate

    Time frame: Baseline to Month 12

  4. Changes from baseline in vital signs through end of study: respiratory rate

    Time frame: Baseline to Month 12

  5. Changes from baseline in vital signs through end of study: blood pressure

    Time frame: Baseline to Month 12

  6. Changes from baseline in vital signs through end of study: pulse oximetry

    Time frame: Baseline to Month 12

  7. Changes from baseline in ECG parameters through end of study: PR interval

    Time frame: Baseline to Month12

  8. Changes from baseline in ECG parameters through end of study: QRS interval

    Time frame: Baseline to Month 12

  9. Changes from baseline in ECG parameters through end of study: QTcF interval

    Time frame: Baseline to Month 12

  10. Changes from baseline in safety laboratory assessments through end of study: serum chemistry

    Time frame: Baseline to Month 12

  11. Changes from baseline in safety laboratory assessments through end of study: hematology

    Time frame: Baseline to Month 12

Secondary outcomes

  1. Pharmacokinetic (PK) for Cizutamig: Cmax

    Time frame: Baseline to Month 12

  2. PK parameters for Cizutamig: time of maximum concentration

    Time frame: Baseline to Month 12

  3. PK parameters for Cizutamig: area under the concentration-time curve

    Time frame: Baseline to Month 12

  4. PK parameters for Cizutamig: clearance

    Time frame: Baseline to Month 12

  5. PK parameters for Cizutamig: volume of distribution

    Time frame: Baseline to Month 12

  6. PK parameters for Cizutamig: half-life

    Time frame: Baseline to Month 12

07

Study locations

17 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 27 months is close to that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Oct 10, 2025
StartActual
Sep 4, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Apr 2028
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07215663
Responsible party
Sponsor
First posted
Oct 10, 2025
Start date
Sep 4, 2025
Primary completion
Dec 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Sep 2, 2026

Study contacts

Liu Tian
Contact
liu@candidrx.com
+86 17621830227

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cizutamig

Start the discussion